Publications by authors named "Yasuhisa Hashino"
Background/aim: Recent lung cancer treatments include an immune checkpoint inhibitor (ICI) pembrolizumab, platinum-based agents, plus an additional cytotoxic anticancer agent. Nutritional indices, such as the geriatric nutritional risk index (GNRI) and the prognostic nutritional index (PNI), are known to correlate with the prognosis of cancer chemotherapy. Several previous studies have investigated the relationship between PNI and treatment response in non-small cell lung cancer patients, reporting significantly increased OS and PFS in the high PNI group before treatment.
View Article and Find Full Text PDFIntroduction: Sotorasib is a crucial therapeutic agent for patients with non-small cell lung cancer (NSCLC) harboring the KRAS p.G12C mutation. Despite its efficacy, the relationship between blood sotorasib concentrations and side effects remains largely unexplored.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to understand how blood levels of Osimertinib affect treatment continuation in patients with EGFR mutation-positive lung cancer.
- It analyzed data from 56 patients and found that higher drug levels correlate with improved progression-free survival (PFS) but did not significantly impact overall treatment efficacy.
- The research concluded that lower serum albumin levels were linked to shorter PFS, potentially influenced by factors like inflammation and liver function in cancer patients.